Screener
Emergent Biosolutions EBS Contracts and grants — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product and services sales, net | $226.8 | $130.3 | $376.5 | $339.4 |
| Contracts and grants | 7.5 | 10.6 | 13.9 | 23.7 |
| Total revenues | 234.3 | 140.9 | 390.4 | 363.1 |
| Operating expenses: | ||||
| Cost of product and services sales, net (1) | 97.1 | 66.9 | 169.1 | 155.4 |
| Research and development | 9.2 | 12.5 | 19.7 | 27.6 |
| Selling, general and administrative | 44.6 | 43.7 | 91.2 | 96.1 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Emergent Biosolutions's contracts and grants — total revenues?
- Emergent Biosolutions (EBS) reported contracts and grants — total revenues of $7.5M in Q2 2026.
- How has Emergent Biosolutions's contracts and grants — total revenues changed year-over-year?
- Emergent Biosolutions's contracts and grants — total revenues decreased by 29.2% year-over-year, from $10.6M to $7.5M.
- What is the long-term trend for Emergent Biosolutions's contracts and grants — total revenues?
- Over 4 years (2021 to 2025), Emergent Biosolutions's contracts and grants — total revenues has grown at a -25.7% compound annual growth rate (CAGR), from $123.8M to $37.7M.
- What does contracts and grants — total revenues mean?
- This metric represents the total revenue recognized from government-funded research, development, and procurement contracts or grants within a specific business segment. It captures the financial contribution of non-commercial partnerships aimed at public health initiatives and product development. Investors use this to assess the company's success in securing public sector funding and the stability of its long-term government-backed revenue streams.
Ask your AI about Emergent Biosolutions's contracts and grants — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude